By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis today said that it has licensed intellectual property covering induced Pluripotent Stem Cells (iPSCs) from iPS Academia Japan.

The non-exclusive licensing deals cover research conducted by Shinya Yamanaka of the Center for iPS Cell Research and Application at Kyoto University in Japan. iPS Academia Japan is an affiliate of Kyoto University established in 2008 to manage IP covering iPSC technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.